Stifel Nicolaus Reaffirms Their Buy Rating on Privia Health Group (PRVA)

In a report released yesterday, Michael Craig Jones from Stifel Nicolaus maintained a Buy rating on Privia Health Group (PRVA – Research Report), with a price target of $24.00. The company’s shares closed yesterday at $18.41.

According to TipRanks, Craig Jones is an analyst with an average return of -4.5% and a 37.50% success rate. Craig Jones covers the Healthcare sector, focusing on stocks such as Agilon Health, Astrana Health, and Alignment Healthcare.

Privia Health Group has an analyst consensus of Strong Buy, with a price target consensus of $27.31, representing a 48.34% upside. In a report released on April 22, Citi also initiated coverage with a Buy rating on the stock with a $25.00 price target.

The company has a one-year high of $30.15 and a one-year low of $17.54. Currently, Privia Health Group has an average volume of 891.3K.

Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Privia Health Group (PRVA) Company Description:

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.